Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Prevention of mother-to-child transmission news

Show

From To
Kenya: 69,000 newborns at risk due to ARVs shortage

Medical personnel at several public hospitals who spoke to the Nation on the condition of anonymity said the shortage began about four months ago. They said the situation is dire, and that if no intervention is made urgently, things could turn disastrous. The administration of ARVs to newborns without HIV is meant to reduce the risk of mother-to-child transmission (perinatal acquisition).

Published
24 June 2019
From
The Nation
Antiretrovirals do not cause neurodevelopmental harm to uninfected infants

In the first five years of life the neurological development of HIV-exposed but uninfected infants, exposed to maternal antiretrovirals before and after birth and throughout breastfeeding, is comparable

Published
24 June 2019
By
Carole Leach-Lemens
What challenges must Nigeria overcome to eliminate vertical transmission of HIV?

Despite impressive health system-related achievements in the prevention of mother-to-child transmission of HIV (PMTCT) in the last decade, Nigeria contributes the greatest number of infants

Published
20 June 2019
By
Carole Leach-Lemens
Breastfeeding with an undetectable viral load: some insights into the current UK situation

Over a third of HIV-positive women in the final stages of pregnancy or who have recently given birth would like to breastfeed, according to research presented to

Published
26 April 2019
By
Michael Carter
A Promising Anti-HIV Drug Poses A Dilemma

The anti-HIV drug dolutegravir is effective — but may carry a risk for pregnant women. While women in wealthy countries are given choices about their medical care, for women in poor countries the situation is different. There aren't enough doctors and nurses to explain the risks and benefits of the new drug to every patient. The country may not have the resources to keep supplies of two different drugs on the shelves. And there is no consistent access to effective birth control.

Published
23 April 2019
From
NPR
Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy.

Published
17 April 2019
From
Medicines and Healthcare products Regulatory Agency
Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

Published
05 April 2019
From
MedPage Today
'Vast majority' of elevated viral load episodes in pregnant women caused by non-adherence

Non-adherence to ART — and not pretreatment drug-resistant mutations — explain the “vast majority” of elevated viral load episodes in women initiating ART during pregnancy, according to results from a study conducted in South Africa.

Published
02 April 2019
From
Healio
HIV antibody VRC01LS safe prevention strategy for infants

Subcutaneous doses of a broadly neutralizing monoclonal antibody, known as VRC01LS, given at birth and 12 weeks were well-tolerated by HIV-exposed infants, according to the results of an open-label safety and pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections. Researchers are studying VRC01LS in combination with ART to prevent HIV infection in neonates.

Published
12 March 2019
From
Healio
Tshepiso study: Preventive TB therapy not associated with poor pregnancy outcomes

Initiating isoniazid preventive therapy for tuberculosis during pregnancy is not associated with a higher rate of poor maternal or infant outcomes, according to observational results from the Tshepiso study presented at CROI.

Published
12 March 2019
From
Healio
← First12345...44Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.